The health system entered into an agreement with Abridge and will use the company’s generative AI to address the challenges associated with clinical documentation, according to a Feb. 23 news release from Abridge.
The primary objective of the initial deployment of the technology is to alleviate the cognitive burden on clinicians, allowing them to devote more time to face-to-face patient interactions rather than being tied to computers.
Abridge also announced a $150 million series C investment, led by Lightspeed Venture Partners. Abridge recently closed out a $30 million series B funding round joined by Somerville, Mass.-based Mass General Brigham Artificial Intelligence and Digital Innovation Fund, Oakland, Calif.-based Kaiser Permanente Ventures and CVS Health Ventures.
